TITLE:
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma

CONDITION:
Colorectal Adenocarcinoma

INTERVENTION:
S-8184 Paclitaxel Injectable Emulsion

SUMMARY:

      Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly
      S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or
      IV colorectal adenocarcinoma.
    

DETAILED DESCRIPTION:

      The goals of this study are to determine the objective response rate, to determine time to
      disease progression, duration of response, and survival, and to identify the maximum
      tolerated weekly dose and principal toxicities of S-8184 in this patient population.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

        Histologic diagnosis of colorectal adenocarcinoma

        Stage III or IV (Dukes's stage C or D)

        One and only one prior cytotoxic chemotherapy regimen which must have included 5-FU

        Adult (18 years of age or older) patients

        Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than
        100,000/mm3)

        Serum creatinine less than 2.0 mg/dL

        Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of
        institutional normal values

        ECOG performance status of 0 - 2

        Bidimensional measurable disease

        Patients who have signed an IRB / Ethics Committee approved informed consent

        Life expectancy at least 12 weeks

        Patient has fully recovered from any previous surgery (at least 4 weeks since major
        surgery)

        Patient has a negative pregnancy test prior to study entry if premenopausal. (Patients of
        child bearing potential must use a medically effective form of contraception during the
        treatment.)

        Exclusion Criteria:

        Patients who have received any taxane-containing preparation including Taxol (paclitaxel)
        or Taxotere (docetaxel)

        Females who are pregnant or lactating

        Patients with peripheral neuropathy NCI-CTC grade 2 or greater

        Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal
        therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of
        study entry

        Patients who have had an investigational agent within 4 weeks of study entry

        Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes
      
